D. Minor

发表

A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma

Kevin B. Kim, D. Char, M. Kashani-Sabet, 2022, Cancer biotherapy & radiopharmaceuticals.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

M. Kashani-Sabet, D. Minor, K. Chin, 2009, Cancer biotherapy & radiopharmaceuticals.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).

G. Linette, J. Wolchok, J. Sosman, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab advanced melanoma (BEAM) was a positive trial.

D. Minor, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous interleukin‐2 and tumor‐infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

N. Barth, R. Dillman, D. Minor, 1991, Cancer.

Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.

N. Barth, R. Dillman, D. Minor, 1991, Molecular biotherapy.

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma

O. Hamid, J. Weber, D. Minor, 2008 .

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

G. Linette, C. Horak, J. Wolchok, 2017 .

Risk of arterial thrombosis not increased by sorafenib or sunitinib.

D. Minor, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.

P. Disaia, D. Minor, C. Brewer, 2003, Gynecologic oncology.

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

Response of patients with Hodgkin's disease to pneumococcal vaccine.

D. Minor, G. Schiffman, L. McIntosh, 1979, Annals of internal medicine.

Impaired response to pneumococcal vaccine in Hodgkin's disease.

J. Ryan, D. Minor, M. Cohen, 1978, The New England journal of medicine.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2015 .

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Kevin B. Kim, B. Andrews, M. Nosrati, 2018, BMC Cancer.

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2014 .

A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.

M. Kashani-Sabet, D. Minor, S. R. Denny, 2005, Cancer biotherapy & radiopharmaceuticals.

Risk of venous thromboembolism with bevacizumab in cancer patients.

D. Minor, 2009, JAMA.

Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated , Relapsed Ovarian Cancer Patients 1

P. Disaia, D. Minor, C. Brewer, 2002 .

Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer

S. P. Moores, J. Chan, D. Minor, 2017, Gynecologic oncology reports.

Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.

J. Wolchok, F. Hodi, M. Sznol, 2012 .

Metastatic islet cell tumor in von Hippel-Lindau disease.

J. Coombs, D. Minor, J. Bennington, 1984, The American journal of medicine.

Case Report of a Pregnancy During Ipilimumab Therapy

Kevin B. Kim, D. Minor, A. Mehta, 2017, Journal of global oncology.

A randomized, double‐blind, placebo‐controlled trial of transfer factor as adjuvant therapy for malignant melanoma

D. Minor, R. Allen, L. Spitler, 1988, Cancer.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

G. Linette, C. Horak, J. Wolchok, 2016, The Lancet. Oncology.

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.

M. Singer, N. Salomonis, S. Millis, 2021, The Journal of investigative dermatology.

Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.

G. Cavet, J. Defalco, W. Robinson, 2017, Clinical immunology.

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

G. Linette, C. Horak, J. Wolchok, 2015 .

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial

S. O’Day, J. Weber, D. Minor, 2011, Melanoma research.

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.

D. Minor, A. Tarhini, Ernest N. Lo, 2010, Cancer biotherapy & radiopharmaceuticals.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

A. Maraveyas, S. O’Day, O. Hamid, 2009, Clinical Cancer Research.

A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma

L. Damico, D. Minor, Uma Suryadevara, 2002, Investigational New Drugs.

The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy

L. Soroceanu, S. Majid, A. Dar, 2015, Journal of the National Cancer Institute.

Sunitinib Therapy for Melanoma Patients with KIT Mutations

S. O’Day, B. Bastian, M. Kashani-Sabet, 2012, Clinical Cancer Research.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

D. Schadendorf, G. Linette, C. Horak, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels.

D. Schadendorf, M. Smylie, B. Neyns, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

D. Schadendorf, P. Ascierto, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Kevin B. Kim, B. Andrews, M. Nosrati, 2018, BMC Cancer.

A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma

D. Alberts, D. Minor, R. Allen, 1985, Cancer.

Chemoablation of metastatic melanoma with rose bengal (PV-10).

M. Ross, B. Coventry, C. Scoggins, 2010 .

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases

M. Kashani-Sabet, S. Leong, D. Schneider, 2013, BMC Anesthesiology.

A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.

D. Alberts, D. Minor, R. Allen, 1986, Cancer.

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

M. Ross, B. Coventry, C. Scoggins, 2014, Annals of Surgical Oncology.

Controlled trial of methotrexate and Bacillus Calmette-Guérin therapy for advanced head and neck cancer.

D. Minor, S. Rudnick, R. Capizzi, 1978, Cancer research.

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

G. Linette, J. Wolchok, F. Hodi, 2016 .

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

Axel Hoos, B. Hug, I. Puzanov, 2015, Pigment cell & melanoma research.

Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial

O. Hamid, J. Weber, D. Minor, 2012, Journal of immunotherapy.

Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02.

M. Ross, B. Coventry, C. Scoggins, 2014 .

23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

G. Linette, J. Sosman, Kevin B. Kim, 2009 .

Treatment of melanoma of the extremities with isolated regional hyperthermic perfusion: 370

S. Leong, D. Minor, R. Allen, 1993 .

Frequency of genetic homologous recombination (HR) alterations in metastatic cutaneous melanoma.

M. Singer, S. Millis, Kevin B. Kim, 2017 .

Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma

O. Hamid, J. Weber, D. Minor, 2008 .

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

S. O’Day, M. Kashani-Sabet, D. Moore, 2009, The oncologist.

Prophylatic cranial irradiation (PCI) in patients (Pts) with stage IV metastatic melanoma (MM) receiving concurrent biochemotherapy (cBCT) and maintenance biotherapy (MBT)

S. O’Day, O. Hamid, J. Weber, 2008 .

Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib

M. Kashani-Sabet, S. Leong, D. Minor, 2012, BMJ Case Reports.

Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.

M. Kashani-Sabet, D. Minor, R. Rodvien, 2012, Melanoma research.

Sunitinib therapy for metastatic melanomas with KIT aberrations.

A. Daud, S. O’Day, B. Bastian, 2010 .

Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.

D. Sze, G. Hwang, D. Minor, 2012, Journal of vascular and interventional radiology : JVIR.

Malignant melanoma of the eye, metastatic after twenty-nine years: a case report.

D. Minor, F. Gatchell, 1972, The Journal of the Oklahoma State Medical Association.

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

M. Kashani-Sabet, D. Moore, D. Minor, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf, P. Ascierto, A. Ribas, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

G. Linette, C. Horak, J. Wolchok, 2016 .

Growth of an Arteriovenous Malformation: A Case Report

D. Minor, T. Gandy, 1977, The Yale journal of biology and medicine.